According to Nanjing Xinbai's announcement, net profit for the first half of 2026 is expected to be 35.1202 million yuan to 38.469 million yuan, a year-on-year decrease of 77.15% to 78.90%. During the reporting period, sales of PROVENGE products of Dendreon Pharmaceuticals LLC controlled by Dendreon Pharmaceuticals LLC, a wholly-owned subsidiary of the company, declined, reducing Shiding Hong Kong's net profit by about 142 million yuan.

Zhitongcaijing · 1d ago
According to Nanjing Xinbai's announcement, net profit for the first half of 2026 is expected to be 35.1202 million yuan to 38.469 million yuan, a year-on-year decrease of 77.15% to 78.90%. During the reporting period, sales of PROVENGE products of Dendreon Pharmaceuticals LLC controlled by Dendreon Pharmaceuticals LLC, a wholly-owned subsidiary of the company, declined, reducing Shiding Hong Kong's net profit by about 142 million yuan.